Literature DB >> 24343668

Haematological cancer: Radioimmunotherapy--time to be upfront and fractionated?

Mina Razzak.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24343668     DOI： 10.1038/nrclinonc.2013.236

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Fractionated ⁹⁰Y-ibritumomab tiuxetan radioimmunotherapy as an initial therapy of follicular lymphoma: an international phase II study in patients requiring treatment according to GELF/BNLI criteria.

Authors:  Tim M Illidge; Sam Mayes; Ruth Pettengell; Andrew T Bates; Mike Bayne; John A Radford; W David J Ryder; Steven Le Gouill; Fabrice Jardin; Jill Tipping; Maureen Zivanovic; Françoise Kraeber-Bodere; Manuel Bardies; Caroline Bodet-Milin; Emmanuel Malek; Damien Huglo; Franck Morschhauser
Journal:  J Clin Oncol       Date:  2013-12-02       Impact factor: 44.544
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.